Entrada Therapeutics, a preclinical biotech developing therapies for rare neuromuscular diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Entrada aims to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV) therapeutics as a new class of medicines. EEV therapeutics are comprised of small cyclic peptides that are chemically conjugated to a wide range of specific and active biological therapeutics. The company is initially focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1. Its most advanced candidate, ENTR-601-44, is being developed for patients with DMD that are exon 44 skipping amenable. Entrada plans to submit an IND application for ENTR-601-44 in 2022.
The Boston, MA-based company was founded in 2016 and plans to list on the Nasdaq under the symbol TRDA. Entrada Therapeutics filed confidentially on August 6, 2021. Goldman Sachs, Cowen, and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
